Os Therapies Incorporated (OSTX)

May 7, 2025, 8:45 AM EDT - 7 days ago

OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040

May 2, 2025, 9:32 AM EDT - 11 days ago

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

Apr 22, 2025, 7:40 AM EDT - 22 days ago

OS Therapies FDA Meeting Request Granted

Apr 10, 2025, 7:42 AM EDT - 4 weeks ago

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

Apr 9, 2025, 7:40 AM EDT - 5 weeks ago

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

Apr 7, 2025, 6:00 AM EDT - 5 weeks ago

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

Apr 2, 2025, 7:40 AM EDT - 6 weeks ago

OS Therapies to Host Analyst Day at NYSE on April 7, 2025

Mar 31, 2025, 4:30 PM EDT - 6 weeks ago

OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update

Mar 31, 2025, 7:40 AM EDT - 6 weeks ago

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

Mar 25, 2025, 7:40 AM EDT - 7 weeks ago

OS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers

Mar 21, 2025, 7:40 AM EDT - 7 weeks ago

OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference

Mar 13, 2025, 7:40 AM EDT - 2 months ago

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

Mar 11, 2025, 7:40 AM EDT - 2 months ago

OS Therapies Schedules United Kingdom's Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

Feb 28, 2025, 9:00 AM EST - 2 months ago

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CLDI

Feb 26, 2025, 4:01 PM EST - 2 months ago

Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on February 27

Feb 24, 2025, 7:25 AM EST - 2 months ago

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

Feb 20, 2025, 5:00 AM EST - 2 months ago

OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2

Feb 14, 2025, 1:51 PM EST - 3 months ago

Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer

Feb 14, 2025, 7:36 AM EST - 3 months ago

OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing

Feb 4, 2025, 7:33 AM EST - 3 months ago

OS Therapies Provides Corporate Update

Jan 16, 2025, 4:06 PM EST - 4 months ago

OS Therapies: A Cheap Mid-Stage Biotech Carrying Listeria-Based Immunotherapy

Jan 15, 2025, 11:18 AM EST - 4 months ago

Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?

Jan 15, 2025, 7:40 AM EST - 4 months ago

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

Jan 2, 2025, 11:16 AM EST - 4 months ago

OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Dec 31, 2024, 3:38 PM EST - 4 months ago

OS Therapies Announces Closing of $6 Million Private Placement

Dec 26, 2024, 10:01 AM EST - 4 months ago

OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online

Dec 24, 2024, 9:32 AM EST - 5 months ago

OS Therapies Announces Pricing of $6 Million Private Placement

Nov 15, 2024, 9:47 AM EST - 6 months ago

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 7:00 AM EST - 6 months ago

OS Therapies to Present at The Spartan Capital Investor Conference

Oct 30, 2024, 8:51 AM EDT - 6 months ago

Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30

Oct 28, 2024, 4:44 PM EDT - 7 months ago

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Oct 24, 2024, 8:46 AM EDT - 7 months ago

OS Therapies to Present at the LD Micro Main Event XVII

Oct 17, 2024, 9:22 AM EDT - 7 months ago

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oct 3, 2024, 12:31 PM EDT - 7 months ago

OSTX CEO: "We Have a Lot of Milestones Coming" in Tumor Research

Oct 3, 2024, 8:00 AM EDT - 7 months ago

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

Sep 13, 2024, 8:09 AM EDT - 8 months ago

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

Sep 11, 2024, 8:15 AM EDT - 8 months ago

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

Sep 5, 2024, 8:22 AM EDT - 8 months ago

OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

Aug 29, 2024, 7:53 AM EDT - 9 months ago

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

Aug 22, 2024, 8:00 AM EDT - 9 months ago

OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

Aug 22, 2024, 6:00 AM EDT - 9 months ago

OS Therapies Clarifies CUSIP of Common Stock

Aug 15, 2024, 8:30 AM EDT - 9 months ago

OS Therapies Reports Second Quarter 2024 Financial Results

Aug 9, 2024, 9:00 AM EDT - 9 months ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

Aug 6, 2024, 8:35 AM EDT - 10 months ago

OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board

Aug 3, 2024, 12:30 AM EDT - 10 months ago

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

ACTU GFL

Aug 2, 2024, 8:55 AM EDT - 10 months ago

OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board

Jul 31, 2024, 6:21 PM EDT - 10 months ago

OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”

Jul 24, 2024, 10:48 AM EDT - 10 months ago

OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer

Jun 3, 2024, 12:44 PM EDT - 1 year ago

OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma